These findings described a miR-181a-TGIF2-Smad-EMT axis in metastatic PCa cells and provide a rationale for a miR-181a targeting strategy as novel therapeutic approach to treat advanced PCa. This evidence concerns the gene TGIF2 and posterior cortical atrophy.